Skip to main content
ISTH 2024 Main banner
Back

Martine Jandrot-Perrus, MD., PhD.

Researcher
Laboratory for Vascular Translational Science, UMR_S1148 INSERM, University Paris Cité, Hôpital Bichat, Paris, France
Paris, Ile-de-France, France

Martine Jandrot-Perrus, MD, PhD, is Emeritus Professor at Inserm U1148 Inserm, Université Paris Cité.
After studying at the Necker-Enfants Malades Faculty of Medicine, she obtained her MD degree in Hematology from the University Paris Descartes. In parallel, she received a scientific training: Bachelor in Biochemistry from University Paris Diderot, Master and thesis in Biochemistry-Enzymology from University Paris Saclay. She completed an internship at the Downstate Medical Center (Brooklyn) under the direction of Professor Mikael Mosesson.
Trained by Professor François Josso, Alan Nurden and Professor Jacques Caen, she oriented her career towards research in hemostasis and thrombosis. She joined the French Institute of Health and Medical Research (Inserm) and directed the team “Molecular mechanisms of Thrombosis and Hemostasis” from 2003 to 2014 in Bichat hospital (Paris).
Martine Jandrot-Perrus’ work is dedicated to understanding the molecular and cellular mechanisms that differentiate pathological thrombosis from physiological hemostasis with a particular interest in the processes taking place at the interface between plasma (coagulation), cells (platelets) and fibrin (fibrinolysis). She contributed to showing the importance of the fibrinogen gamma chain at the platelet level, to characterizing the interaction of thrombin with platelet glycoprotein Ib and she initiated the study of protease nexin-1, a platelet inhibitor of coagulation and fibrinolysis. Her major contribution concerns platelet glycoprotein VI with the identification of a specific ligand, convulxine, GPVI cloning, molecular and cellular characterisation. Her work contributed to show that GPVI is incidental to physiological hemostasis but critical in the initiation and progression of thrombosis and thromboinflammation leading to a paradigm shift and opening the way to the development of antiplatelet drugs whose effectiveness is disconnected from the risk of bleeding. She co-founderd Acticor-Biotech in 2013 to develop a therapeutic GPVI antagonist, glenzocimab, which is evaluated in various clinical trials, particularly in ischemic stroke.

Presentation(s):